Fast track would be nice and definitely do-able. But don't hold your breath. Even with recent legislation to speed-up the process, I'm unaware of a drug that hasn't had to complete Phase One before getting that status. I'm sure there are several big pharmas watching this one, but none will make an offer before know the outcome of human trials that dose-limiting toxicity is within safe levels. No imminent buyout possibilities for quite a while. Accumulate shares steadily now and get giddy later.
Market Data 
Markets 
AI
